

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 3, 2023
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:10 p.m. on Wednesday, May 3, 2023.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Divya Ahuja, MD	Edward Behling, MD	Duncan Norton, MD
Kimberly Rudd, MD	Jony Bolinger, MD	Phillip Mubarak, MD
Cheryl Hartvigsen, RPh	Thomas Phillips, RPh	Gregory Browning, MD
Erika Tillery, PharmD	Patricia Witherspoon, MD	Kelly Barth, MD

SC DHHS Staff:

Cheryl Anderson BS, RPh
Kevin Wessinger, MD
Sarah Hearn-Baily, JD
Kim Bristow, RPh
Brandie Crider
Ashley Sirianni, DNP, FNP-BC

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, February 1, 2023

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class

¹ No speakers

C. Drug Classes for Review

Classes for Re-Review

- Beta Adrenergic Devices, Short Acting Inhalers
- Androgenic Agents, Topical
- Opioids Extended Release, Oral
- Sodium-Glucose Transporter 2 (SGLT2) Inhibitors

The chart below represents the recommendations from the P & T Committee:

BETA ANDRENERGIC DEVICES, SHORT ACTING INHALERS	
<i>This class was scheduled to be re-reviewed as a result of the Public Health Emergency (PHE) ending. SC Medicaid removed coding during the PHE allowing access to all products. However, given the volatility which remains within this class (shortages, discontinuations) the class will remain “open” and may be revisited in the future.</i>	
ANDROGENIC AGENTS, TOPICAL	
Preferred	Non-Preferred
Testosterone gel 1.62% pump‡	Androderm®
Testim®‡	Androgel® 1%
	Androgel®+ 1.62%
	Natesto®
	Testosterone gel
	Testosterone solution
OPIOIDS EXTENDED RELEASE, ORAL	
Preferred	Non-Preferred
Morphine Sulfate SA	Belbuca®
Xtampza ER®‡	Hyslingla® ER
	Hydrocodone ER capsule
	Hydromorphone ER tab
	Oxycodone SR
	Oxymorphone ER
	Tapentadol ER
	Tramadol ER

SGLT2 (SODIUM GLUCOSE TRANSPORTER 2) INHIBITORS	
Preferred	Non-Preferred
Farxiga®	Invokamet® XR
Invokana®	Segluromet®
Invokamet®	Steglatro®
Jardiance®	Synjardy® / Synjardy® XR
Xigduo® XR‡	Trijardy® XR

- ‡ Added as “Preferred”
- + Moved to “Non-Preferred”

5. Old Business

None

6. New Business

Dr. Wessinger, Chief Medical Officer, shared the revised Hepatitis C Prior Authorization form which now aligns with AASLD (American Association for the Study of Liver Disease) guidelines. Prescriber restrictions, race indicator and substance use/sobriety questions were removed from the form. Class level prior authorization remains in effect. Cheryl Anderson, SC Pharmacy Director, provided policy updates. Coverage of hemophilia products was migrated from SC DHEC to “any willing provider” effective March 1, 2023. Senate Bill 628, Pharmacy Access Act, was introduced on March 2, 2021 and will go into effect on October 1, 2023. SC DHHS is crafting a provider notice which will be distributed at least 30 days prior to October 1st. Training sessions will be available to educate pharmacists on appropriate codes to use and billing.

Lisa Correll presented new drugs to market. Also, annual Pharma meeting notices have been sent. Meetings remain virtual for 2023.

7. Resolved Items

Classes for Re-Review

- Beta Adrenergic Devices, Short Acting Devices
- Androgenic Agents, Topical
- Opioids Extended Release, Oral
- Sodium-Glucose Transporter 2 (SGLT2) Inhibitors

8. Closing Comments

The next meeting will be held Wednesday, August 2, 2023.

9. Adjournment

The meeting adjourned at 4:57 p.m.